Lisinopril Pharmacogenomics and Genetic Variability

How Lisinopril Works at the Molecular Level

Lisinopril binds the zinc ion at the active site of angiotensin-converting enzyme, blocking the conversion of angiotensin I to angiotensin II. This lowers arterial resistance. It also slows bradykinin degradation, which contributes to vasodilation but explains the dry cough that affects 5% to 35% of users depending on the population studied [1].

Unlike enalapril or ramipril, lisinopril is not a prodrug. It arrives at the ACE active site in its pharmacologically active form without hepatic conversion. This means cytochrome P450 polymorphisms (CYP2D6, CYP3A4, CYP2C19) that alter the activation of other ACE inhibitors have no bearing on lisinopril pharmacokinetics [2]. The drug is absorbed from the GI tract with roughly 25% bioavailability, circulates without protein binding, and is excreted entirely unchanged by the kidneys. Renal function, not liver enzyme genotype, dictates clearance.

This pharmacokinetic simplicity makes lisinopril an unusual case in cardiovascular pharmacogenomics. The genetic variability that matters is pharmacodynamic: polymorphisms in the drug's target (ACE), upstream substrate (angiotensinogen), downstream receptor (AT1R), and the bradykinin pathway it incidentally modulates [3].

The ACE Insertion/Deletion Polymorphism

The single most studied genetic variant in ACE inhibitor pharmacogenomics is a 287-base-pair Alu repeat insertion/deletion (I/D) in intron 16 of the ACE gene (chromosome 17q23). Three genotypes exist: II, ID, and DD.

Rigat et al. demonstrated in 1990 that this polymorphism accounts for 47% of the total variance in plasma ACE concentrations [4]. DD homozygotes have roughly twice the circulating ACE levels of II homozygotes. ID heterozygotes fall in between. The allele frequencies vary by ancestry: the D allele frequency is approximately 0.55 in European populations, 0.60 to 0.65 in populations of African descent, and 0.39 in East Asian populations [5].

What does this mean for lisinopril? Higher baseline ACE activity in DD patients means a fixed dose of lisinopril inhibits a smaller fraction of total enzyme. A 2003 meta-analysis published in Pharmacogenetics found that DD genotype carriers had a 2 to 4 mmHg smaller systolic blood pressure reduction compared to II carriers on equivalent ACE inhibitor doses [6]. That gap sounds modest. Over 10 years, a persistent 3 mmHg systolic difference translates to roughly 12% higher stroke risk according to Prospective Studies Collaboration data [7].

The clinical question is whether genotyping should guide initial dose selection. Current evidence suggests the answer is "not yet for routine practice" but "plausibly useful for refractory patients." The Pharmacogene Variation Consortium (PharmVar) catalogs ACE I/D, but neither CPIC nor DPWG has issued a prescribing guideline. Dr. Julie Johnson, director of the University of Florida Center for Pharmacogenomics, has noted: "ACE I/D is one of the most replicated pharmacogenomic associations in cardiovascular medicine, but effect sizes in individual patients are modest enough that routine preemptive testing isn't cost-justified with current evidence" [8].

Angiotensinogen (AGT) M235T and Upstream RAAS Variants

The ACE I/D polymorphism does not act alone. Angiotensinogen (AGT), the precursor protein that ACE cleaves, has its own common variant: a methionine-to-threonine substitution at position 235 (M235T, rs699). The 235T allele is associated with 10% to 20% higher plasma angiotensinogen levels [9]. In theory, more substrate means more angiotensin II production, which could either increase the benefit of ACE inhibition (more target to block) or overwhelm a standard dose.

Data from a substudy of the AASK trial (African American Study of Kidney Disease) showed that AGT 235TT homozygotes on ramipril had less renal protection than MT or MM genotypes, suggesting the variant may blunt ACE inhibitor efficacy in high-substrate states [10]. While this trial used ramipril rather than lisinopril, the pharmacodynamic principle applies to the drug class.

The renin gene (REN) and the angiotensin II type 1 receptor gene (AGTR1) add further complexity. The AGTR1 A1166C polymorphism (rs5186) has been linked to differential blood pressure response to losartan in some studies, but data specific to ACE inhibitors remain inconsistent [11]. A 2019 systematic review in Clinical Pharmacology & Therapeutics concluded that multi-gene panels combining ACE I/D, AGT M235T, and AGTR1 A1166C explained more variance in blood pressure response than any single variant, but prospective validation trials are still lacking [12].

Ancestry, ALLHAT, and Population-Level Genetic Architecture

The ALLHAT trial (N=33,357) remains the largest randomized comparison of first-line antihypertensives. In the overall cohort, lisinopril produced equivalent primary cardiovascular outcomes to chlorthalidone. But the prespecified subgroup of Black participants (N=15,094) showed a 40% higher relative risk of stroke (6-year rate 6.3% vs. 5.0%, RR 1.40 to 95% CI 1.17 to 1.68) and 32% higher heart failure incidence with lisinopril compared to chlorthalidone [13].

This finding is not purely genetic. It reflects a complex interplay of salt sensitivity prevalence, lower baseline renin levels, dietary sodium intake, and yes, allele frequency differences in RAAS pathway genes. Populations of African descent have higher average D allele frequency at the ACE locus, higher AGT 235T frequency (approximately 0.80 vs. 0.40 in European populations), and different distributions of epithelial sodium channel variants that favor volume-dependent hypertension [14].

The 2017 ACC/AHA Hypertension Guideline states: "In Black patients, including those with diabetes, a thiazide-type diuretic or CCB is recommended as initial therapy instead of an ACE inhibitor" (Class I, Level A) [15]. This recommendation integrates ALLHAT outcomes, RAAS biology, and population-level pharmacogenomic signals, even though it does not mandate individual genotyping. The guideline recognizes that within any ancestry group, individual genotypes vary, and a Black patient with an II genotype and high-renin hypertension may respond excellently to lisinopril.

Bradykinin Pathway Genetics and ACE Inhibitor Cough

ACE inhibitor cough affects between 5% and 35% of patients across populations, with higher rates consistently observed in East Asian cohorts and in women [16]. The mechanism involves accumulation of bradykinin and substance P due to ACE inhibition. Bradykinin signals through two receptors, B1 (BDKRB1) and B2 (BDKRB2), and polymorphisms in both genes modify cough susceptibility.

The most replicated variant is BDKRB2 -58T/C (rs1799722). A 2012 meta-analysis of 11 studies (N=4,267) published in Pharmacogenomics found that the CC genotype was associated with significantly lower cough risk (OR 0.46 to 95% CI 0.30 to 0.71) compared to TT carriers [17]. The -58C allele reduces BDKRB2 transcription, resulting in fewer B2 receptors and less bradykinin-mediated airway irritation.

This is clinically actionable in principle. A patient on lisinopril who develops persistent dry cough could be genotyped for BDKRB2 -58T/C. A TT result would confirm genetic predisposition and support switching to an ARB. A CC result would prompt investigation of other cough causes before abandoning a well-tolerated antihypertensive.

Dr. Dan Roden, founding director of the Vanderbilt PREDICT pharmacogenomics program, has observed: "Bradykinin receptor variants represent one of the clearest examples where a pharmacogenomic test could reduce unnecessary drug switching, but the test cost currently exceeds the cost of simply trying an ARB" [18].

CYP Independence: Why Lisinopril Is Pharmacokinetically Simple

Among the 13 ACE inhibitors available in the United States, lisinopril and captopril are the only two that do not require hepatic activation. Every other ACE inhibitor (enalapril, ramipril, benazepril, fosinopril, quinapril, perindopril, trandolapril, moexipril) is administered as a prodrug that requires esterase-mediated cleavage in the liver to generate the active diacid form [2].

This distinction has pharmacogenomic implications. Enalapril activation, for example, depends on carboxylesterase 1 (CES1). The CES1 G143E loss-of-function variant (rs71647871), found in approximately 3.7% of individuals with European ancestry and 4.3% of those with African ancestry, reduces enalaprilat formation by roughly 50% [19]. Carriers may have subtherapeutic active drug levels on standard enalapril doses.

Lisinopril sidesteps this entirely. No prodrug activation. No CYP metabolism. No CES1 dependence. The only pharmacokinetic variable that alters lisinopril exposure is glomerular filtration rate. Patients with eGFR <30 mL/min/1.73 m² accumulate the drug and require dose reduction per the FDA label, but this is measured by a simple blood test, not a genotype [20].

Multi-Gene Panels and the Future of ACE Inhibitor Prescribing

Genome-wide association studies (GWAS) have identified additional loci beyond the classical RAAS pathway that influence blood pressure response to antihypertensives. The PEAR study (Pharmacogenomic Evaluation of Antihypertensive Responses, N=768) genotyped participants on either atenolol or hydrochlorothiazide across 768,000+ SNPs and identified novel loci influencing treatment response [21]. A companion PEAR-2 study examined ACE inhibitor response specifically.

The PEAR-2 findings, published in 2021, showed that a polygenic score incorporating 900+ variants explained approximately 3% to 5% of blood pressure response variance on perindopril [22]. While modest, this exceeds the predictive power of any single candidate gene. Translating this approach to lisinopril would require a dedicated replication cohort.

The Implementation of Pharmacogenetics in Primary Care (PREPARE) trial in the Netherlands (N=6,944) randomized patients to either preemptive 12-gene pharmacogenomic panel testing or standard care. ACE inhibitors were not among the 42 drugs covered by the DPWG guidelines used in the trial, but the study demonstrated that panel-based preemptive testing reduced clinically significant adverse drug reactions by 30% (OR 0.70 to 95% CI 0.54 to 0.91) across included medications [23]. If ACE I/D and BDKRB2 variants are added to future panel iterations, lisinopril prescribing could be included.

Clinical Decision Points Where Genotype Might Matter Now

Three scenarios exist where pharmacogenomic thinking, even without formal testing, can inform lisinopril prescribing today.

Refractory hypertension on monotherapy. A patient with uncontrolled blood pressure on lisinopril 40 mg daily may carry the DD genotype. Rather than uptitrating beyond the ceiling dose, adding a thiazide diuretic or CCB addresses the hemodynamic gap. The JNC 8 panel and 2017 ACC/AHA guideline both recommend combination therapy when monotherapy fails, and RAAS pharmacogenomics provides a mechanistic rationale for why some patients fail earlier [15].

Persistent cough within weeks of initiation. If a patient develops cough on lisinopril, the TT genotype at BDKRB2 -58T/C raises the probability that bradykinin accumulation is the cause. Switching to losartan or valsartan eliminates ACE-mediated bradykinin effects while maintaining RAAS blockade.

Ancestry-informed first-line selection. The ALLHAT data showing worse stroke outcomes in Black patients on lisinopril reflect, in part, population-level RAAS gene architecture. Starting with amlodipine or chlorthalidone as first-line, with lisinopril added as second-line combination therapy, aligns with both guideline recommendations and pharmacogenomic principles [13][15].

What Clinicians Should Track Going Forward

CPIC is actively evaluating the evidence base for cardiovascular pharmacogenomic guidelines. The PharmGKB database currently assigns a level 2A evidence rating (moderate evidence) to the ACE I/D association with ACE inhibitor response [24]. Elevation to level 1A would likely trigger a CPIC guideline and could shift the threshold for routine testing.

Until that threshold is crossed, the practical stance for prescribers is to recognize that lisinopril's pharmacodynamic variability is real, genetically influenced, and partially predictable by ancestry and family history of ACE inhibitor response. A patient whose parent or sibling failed lisinopril due to cough or inadequate BP reduction carries informative genetic risk, even without a formal genotype result. Dose adjustments for renal function remain the only FDA-mandated pharmacogenomic-adjacent requirement: reduce the starting dose to 5 mg when eGFR falls below 30 mL/min/1.73 m² [20].